Obalon Announces Fourth Quarter and Full Year 2017 Financial Results
05 mars 2018 15h01 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...
Obalon Schedules Fourth Quarter and Year End 2017 Financial Results Conference Call for March 5, 2018 at 5:00 p.m. Eastern Time
05 mars 2018 09h01 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...
Obalon’s Audit Committee Investigation of Whistleblower Allegation Finds Complaint Meritless
20 févr. 2018 07h01 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN) today announced the Audit Committee has completed its investigation into a purported whistleblower complaint and...
Obalon Announces Termination of Public Offering of Common Stock
23 janv. 2018 09h13 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (the “Company” or “Obalon”) (NASDAQ:OBLN) today announced the termination of the underwriting agreement and cancellation of its...
Obalon Therapeutics Prices Public Offering of Common Stock
18 janv. 2018 22h00 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical device company with the first and only FDA-approved swallowable, gas-filled...
Obalon Therapeutics Announces Proposed Public Offering of Common Stock
16 janv. 2018 16h01 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical device company with the first and only FDA-approved swallowable, gas-filled...
Obalon Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Full Year 2017
05 janv. 2018 08h00 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN) today reported that it achieved preliminary, unaudited revenue of approximately $3.9 million for the fourth...
Obalon Schedules Fourth Quarter and Full Year 2017 Preliminary, Unaudited Revenue and Business Update Conference Call for January 5, 2018 at 8:30 a.m. Eastern Time
04 janv. 2018 17h15 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...
Obalon Announces Upcoming Conference Presentations
06 nov. 2017 08h46 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...
Obalon Announces Third Quarter 2017 Financial Results
03 nov. 2017 07h29 HE
|
Obalon Therapeutics, Inc.
SAN DIEGO, Nov. 03, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...